GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Journal Article

Single intradermal or intramuscular inoculations of GM-CSF DNA with the DNA prime for a simian-human immunodeficiency virus (SHIV)-89.6 vaccine, which consists of DNA priming followed by modified vaccinia Ankara (MVA) boosting, increased protection of both the blood and intestines against the acute phase of an intrarectal SHIV-89.6P challenge. GM-CSF appeared to contribute to protection by enhancing two antibody responses: the avidity maturation of anti-Env IgG in blood (p=or<0.01) and the presence of long lasting anti-viral IgA in rectal secretions (p<0.01). The avidity of anti-Env IgG showed strong correlations with protection both pre and post challenge. Animals with the highest avidity anti-Env Ab had 1000-fold reductions in peak viremia over those with the lowest avidity anti-Env Ab. The enhanced IgA response was associated with the best protection, but did not achieve significance.

Full Text

Duke Authors

Cited Authors

  • Lai, L; Vödrös, D; Kozlowski, PA; Montefiori, DC; Wilson, RL; Akerstrom, VL; Chennareddi, L; Yu, T; Kannanganat, S; Ofielu, L; Villinger, F; Wyatt, LS; Moss, B; Amara, RR; Robinson, HL

Published Date

  • December 5, 2007

Published In

Volume / Issue

  • 369 / 1

Start / End Page

  • 153 - 167

PubMed ID

  • 17698160

International Standard Serial Number (ISSN)

  • 0042-6822

Digital Object Identifier (DOI)

  • 10.1016/j.virol.2007.07.017

Language

  • eng

Conference Location

  • United States